Alkem Laboratories Launches Generic Empagliflozin in India Under Brand Name 'Empanorm'

Alkem Laboratories Ltd has announced the launch of generic empagliflozin and its combinations in India under the brand name ‘Empanorm’. The prices are approximately 80% lower than the innovator products. Empagliflozin is an SGLT-2 inhibitor used in the treatment of type-2 diabetes mellitus, chronic kidney disease, and chronic heart failure. Alkem's generic empagliflozin and its combinations are bioequivalent to innovator products. The company has introduced anti-counterfeit security bands and comprehensive patient education information on diabetes management in 11 languages. The medicine is available in a smaller tablet size for patient convenience.